CTRI/2010/091/000031已完成2 期
A Randomized, Double Blind, Comparative, Phase II/III Study to Evaluate the Immunogenicity and Safety of Three Formulations [15 mcg (unadjuvanted), 7.5 mcg (adjuvanted) and 3.75 mcg (adjuvanted)] of Monovalent H1N1 Influenza A (2009) Virus Vaccine, Manufactured by Panacea Biotec Ltd., in Healthy Pediatric Population 3 - 9 Years of Age. - H1N1 3-9year
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects aged 3- 9 years whose parents/LAR gives a written informed consent prior to the study entry.
- •2.Subjects with good health as determined by:
- •- Medical history
- •- Physical examination
- •- Clinical judgment of the investigator
排除标准
- •1.The parents or LAR are unwilling or unable to give written informed consent to participate in the study.
- •2.The subject (7- 9 years) who does not assent to participate in the study.
- •3.The subject is a case, cured case or has a history of close contact with influenza A (H1N1) virus infected patients.
- •4.Subject having history of previous immunization with any pandemic or seasonal influenzae vaccine.
- •5.Subject with history of systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances
- •6.Has received any live licensed vaccines within 4 weeks or inactivated licensed vaccines within 2 weeks prior to vaccination in this study, or plan receipt of such vaccines within 21 days following the second vaccination. The initiation of this protocol does not take precedence over routine immunizations.
- •7. Has a history of severe reactions following previous immunization with influenza virus vaccines
- •8.Subject allergic to egg or egg protein.
- •9.Subjects who are taking any antiviral drug either for treatment or prophylaxis against infection.
- •10.Have immunosuppression as a result of an underlying illness or treatment, or use of anticancer chemotherapy or radiation therapy (cytotoxic) within the preceding 36 months.
- •11.Have long term use of glucocorticoids including oral, parenteral or high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months. (Nasal and topical steroids are allowed.)
- •12.Have an active neoplastic disease or a history of any hematologic malignancy.
- •13.Axillary temperature > 37.0 centigrade in past 3 days.
- •14.Presence or past history of significant cardiovascular, hepatic, renal, pulmonary (including respiratory depression or diseases involving obstruction/ narrowing of airways), gastrointestinal, endocrine (including past history of thyroidectomy or thyroid disease, Diabetes mellitus), dermatological, neurological (including encephalopathy, seizure/epilepsy history and/or taking anti-seizure medication etc.) or psychiatric disease or disorder or autoimmune disease that in the opinion of the investigator, places the participant at an unacceptable risk of injury, render the participant unable to meet the requirements of the protocol, or interfere with the successful completion of the study..
- •15.Any history suggestive of thrombocytopenia or a bleeding disorder.
- •16.Subjects with Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen
- •17.Subjects with history of Guillain-Barre Syndrome
- •18.Any evidence of acute illness or infection requiring systemic antibiotic therapy within past 7 days.
- •19.Subjects who have received any blood transfusion, immunoglobulin or other blood product within the 3 months prior to vaccination in this study.
- •20.Self-reported seropositivity for human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C infection or autoimmune hepatitis.
- •21.Family members of the employees of the study centre or the Investigator.
- •22.Receipt of any allergy shots and/or seasonal allergy medication in the 7-day period prior to enrollment (vaccination), or scheduled to receive any allergy shots and/or seasonal allergy medication in the 7-day period after enrollment (vaccination)
- •23.Subjects who have participated in another trial of an investigational agent within 30 days of enr
研究者
相似试验
已完成
2 期
A Phase II/III clinical Study to Evaluate the Immunogenicity and Safety of Three Formulations of Monovalent H1N1 Influenza A (2009) Virus Vaccine, Manufactured by Panacea Biotec Ltd., in Healthy Pediatric Population 6 - 35 Months of Age.CTRI/2010/091/000029Panacea Biotec Limited360
已完成
2 期
A phase II/III clinical study to evaluate the immunogenicity and safety of three formulations of monovalent H1N1 influenza A (2009) virus vaccine in healthy adults.CTRI/2010/091/000032Panacea Biotec Limited360
进行中（未招募）
不适用
Phase II, double blind, randomized, comparative study of the immunogenicity and safety of GlaxoSmithKline Biologicals’ modified formulation varicella vaccine and Varilrix™ given as a 2 dose course in the second year of life - OKA-H-186Primary vaccination against varicella in healthy children in their second year of lifeEUCTR2007-000683-24-HUGlaxoSmithKline Biologicals240
进行中（未招募）
1 期
Phase II, double blind, randomized, comparative study of the immunogenicity and safety of GlaxoSmithKline Biologicals’ modified formulation varicella vaccine and Varilrix™ given as a 2 dose course in the second year of life - OKA-H-186Primary vaccination against varicella in healthy children in their second year of lifeEUCTR2007-000683-24-CZGlaxoSmithKline Biologicals244
进行中（未招募）
1 期
A Phase II, Double Blind, Randomised, Controlled, Multi-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of Three Formulations of CSL412 in Adults (= 18 to = 45 years) and Older Adults (= 60 years).Prophylaxis of InfluenzaEUCTR2007-000272-16-GBCSL Limited720